DNA copy number gains in malignant pleural mesothelioma

Furukawa,Masashi; Toyooka,Shinichi; Hayashi,Tatsuro; Yamamoto,Hiromasa; Fujimoto,Nobukazu; Soh,Junichi; Hashida,Shinsuke; Shien,Kazuhiko; Asano,Hiroaki; Aoe,Keisuke; Okabe,Kazunori; Pass,Harvey  I.; Tsukuda,Kazunori; Kishimoto,Takumi; Miyoshi,Shinichiro

doi:10.3892/ol.2015.3652

DNA copy number gains in malignant pleural mesothelioma

Authors:
- Masashi Furukawa
- Shinichi Toyooka
- Tatsuro Hayashi
- Hiromasa Yamamoto
- Nobukazu Fujimoto
- Junichi Soh
- Shinsuke Hashida
- Kazuhiko Shien
- Hiroaki Asano
- Keisuke Aoe
- Kazunori Okabe
- Harvey I. Pass
- Kazunori Tsukuda
- Takumi Kishimoto
- Shinichiro Miyoshi
View Affiliations

Affiliations: Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700‑8558, Japan, Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Okayama 702‑8055, Japan, Department of Medical Oncology, National Hospital Organization Yamaguchi‑Ube Medical Center, Ube, Yamaguchi 755‑0241, Japan, Department of Thoracic Surgery, National Hospital Organization Yamaguchi‑Ube Medical Center, Ube, Yamaguchi 755‑0241, Japan, Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York University Langone Medical Center, NY 10016, USA
Published online on: August 27, 2015 https://doi.org/10.3892/ol.2015.3652
Pages: 3274-3278

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an extremely poor prognosis. The incidence of MPM is increasing as a result of widespread exposure to asbestos. The molecular pathogenesis of MPM remains unclear. The present study analyzed the frequency of various genomic copy number gains (CNGs) in MPM using reverse transcription‑quantitative polymerase chain reaction. A total of 83 primary MPMs and 53 primary lung adenocarcinomas were analyzed to compare the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2. In MPM, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 12 (14.5%), 8 (9.6%), 5 (6.0%), 4 (4.8%) and 1 (1.2%) of the samples, respectively. In lung adenocarcinomas, the CNGs of EGFR, KRAS, MET, FGFR1 and SOX2 were detected in 21 (39.6%), 12 (22.6%), 5 (9.4%), 10 (18.9%) and 0 (0.0%) of the samples, respectively. The CNGs of EGFR, KRAS and FGFR1 were significantly less frequent in the MPMs compared with the lung adenocarcinomas (P=0.0018, 0.048 and 0.018, respectively). Overall, the MPMs exhibited these CNGs less frequently compared with the lung adenocarcinomas (P=0.0002). The differences in CNGs between the two tumor types suggested that they are genetically different.

View Figures

View References

1	Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, Harlow BL and Benichou J: Malignant mesothelioma: Attributable risk of asbestos exposure. Occup Environ Med. 51:804–811. 1994. View Article : Google Scholar : PubMed/NCBI
2	Björkqvist AM, Tammilehto L, Nordling S, Nurminen M, Anttila S, Mattson K and Knuutila S: Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer. 77:260–269. 1998. View Article : Google Scholar : PubMed/NCBI
3	Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, et al: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 98:438–446. 2007. View Article : Google Scholar : PubMed/NCBI
4	Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS and Dacic S: Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 21:742–747. 2008. View Article : Google Scholar : PubMed/NCBI
5	Toyooka S, Kishimoto T and Date H: Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama. 62:1–7. 2008.PubMed/NCBI
6	Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, Levy F, Janin A, Giovannini M and Jaurand MC: Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene. 22:3799–3805. 2003. View Article : Google Scholar : PubMed/NCBI
7	Nemoto H, Tate G, Kishimoto K, Saito M, Shirahata A, Umemoto T, Matsubara T, Goto T, Mizukami H, Kigawa G, et al: Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum. Cancer Genet. 205:594–598. 2012. View Article : Google Scholar : PubMed/NCBI
8	Metcalf RA, Welsh JA, Bennett WP, et al: p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 52:2610–2615. 1992.PubMed/NCBI
9	Papp T, Schipper H, Pemsel H, et al: Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol. 18:425–433. 2001.PubMed/NCBI
10	Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, et al: Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res. 61:5727–5730. 2001.PubMed/NCBI
11	Kobayashi N, Toyooka S, Yanai H, et al: Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer. 62:120–125. 2008. View Article : Google Scholar : PubMed/NCBI
12	Goto Y, Shinjo K, Kondo Y, et al: Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 69:9073–9082. 2009. View Article : Google Scholar : PubMed/NCBI
13	Addis B and Roche H: Problems in mesothelioma diagnosis. Histopathology. 54:55–68. 2009. View Article : Google Scholar : PubMed/NCBI
14	Gee GV, Koestler DC, Christensen BC, et al: Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 127:2859–2869. 2010. View Article : Google Scholar : PubMed/NCBI
15	Betta PG, Magnani C, Bensi T, Trincheri NF and Orecchia S: Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med. 136:253–261. 2012. View Article : Google Scholar : PubMed/NCBI
16	Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, et al: International Mesothelioma Interest Group: Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 137:647–667. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, et al: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68:6913–6921. 2008. View Article : Google Scholar : PubMed/NCBI
18	Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
19	Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, et al: MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 124:1778–1784. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M and Fujii Y: Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single-nucleotide polymorphism array analysis. Cancer Res. 65:5561–5570. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, et al: Sex-determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 5:e91122010. View Article : Google Scholar : PubMed/NCBI
23	Kohler LH, Mireskandari M, Knösel T, Altendorf-Hofmann A, Kunze A, Schmidt A, Presselt N, Chen Y and Petersen I: FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch. 461:49–57. 2012. View Article : Google Scholar : PubMed/NCBI
24	Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA and Iafrate AJ: FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 7:1775–1780. 2012. View Article : Google Scholar : PubMed/NCBI
25	Sasaki H, Yokota K, Hikosaka Y, Moriyama S, Yano M and Fujii Y: Increased SOX2 copy number in lung squamous cell carcinomas. Exp Ther Med. 3:44–48. 2012.PubMed/NCBI
26	Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, et al: Functional analysis of c-met hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66:352–361. 2006. View Article : Google Scholar : PubMed/NCBI
27	Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
28	Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006. View Article : Google Scholar : PubMed/NCBI
29	Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M and Fujii Y: Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 134:1105–1111. 2008. View Article : Google Scholar : PubMed/NCBI
30	Rena O, Boldorini LR, Gaudino E and Casadio C: Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations. J Surg Oncol. 104:701–705. 2011. View Article : Google Scholar : PubMed/NCBI
31	Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E, Iizuka N, Maruyama H, Haratake J, Kojima Y, et al: A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int. 62:226–231. 2012. View Article : Google Scholar : PubMed/NCBI
32	Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Iizuka N, Maruyama H and Nonomura A: Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J Clin Pathol. 65:77–82. 2012. View Article : Google Scholar : PubMed/NCBI
33	Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 51:207–215. 2006. View Article : Google Scholar : PubMed/NCBI
34	Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, Taatjes DJ and Mossman BT: Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol. 152:333–340. 1998.PubMed/NCBI
35	Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI and Everson RB: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 118:521–522. 2006. View Article : Google Scholar : PubMed/NCBI
36	Velcheti V, Kasai Y, Viswanathan AK, Ritter J and Govindan R: Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol. 4:5592009. View Article : Google Scholar : PubMed/NCBI
37	Mezzapelle R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso O, et al: Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 108:1743–1749. 2013. View Article : Google Scholar : PubMed/NCBI
38	Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
39	Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S and Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6:279–286. 2005. View Article : Google Scholar : PubMed/NCBI
40	Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL: Cancer and Leukemia Group B (CALGB 30101): Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 11:2300–2304. 2005. View Article : Google Scholar : PubMed/NCBI
41	Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA and Borden EC: Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol. 25:2406–2413. 2007. View Article : Google Scholar : PubMed/NCBI